GRF(1-29) comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
December 15: The Soviet Union withdraws from Iran. Both the Azerbaijan People's Government and the Republic of Mahabad are dissolved. December 19: The First Indochina War begins between the communist-controlled Viet Minh and the French.
He intended for the new Hibiscus to be open by September, and to transfer over the style of cooking he had used in Ludlow, saying, "I'm transferring Hibiscus, not starting a new restaurant. The idea is to continue and build on what I have been doing." Purchasing and fitting out the London premises cost around £1 million. Many of the staff from the Ludlow incarnation of Hibiscus agreed to move to London to continue working at the restaurant, including head chef Marcus McGuinness and sommelier Simon Freeman. Hibiscus re-opened in October 2007 in its new location after following building works and planning delays. The interior of the London-based restaurant was decorated in orange and shades of brown. The walls were covered in pale-coloured wooden panels, and a chandelier designed as a series of globes hungs from the middle of the main dining room's ceiling. The handover on the first day was so tight that builders moved out at midday, and the first service was run at 7 pm that evening. The late opening resulted in the reviewers for the Michelin Guide having only a two-week window in which to re-assess the restaurant for the 2008 guide. Bosi admitted later that the restaurant was not yet up to scratch in those two weeks and agreed with the decision of Michelin to downgrade Hibiscus to a single star in the 2008 Guide. The restaurant was also given a "rising star" as one with potential to go up to two stars in the future. During the run up to Christmas, the stress of serving 550 covers a week in a new location with a modified menu resulted in three sous chefs resigning.
== See also == Adipose tissue Appetite Basal metabolic rate Energy homeostasis Glucagon Glycemic index Glycemic load Hyperinsulinemia Insulin sensitivity Insulin Ketogenic diet Leptin Lipogenesis Low-carbohydrate diet Low-glycemic index diet Metabolic Syndrome Obesity Refined carbohydrates Set point theory Sugar Ultra-processed food
Sources: en.wikipedia.org
=== False eggs === Calculus: Calculi are egg-like objects formed in the stomachs of ruminants such as cattle, deer, elk, and goats. Calculus formation is a defense mechanism protecting the ruminant's stomach from damage if it swallows a foreign object while grazing. After ingestion, the object is covered by the same material composing bone, calcium phosphate, and eventually vomited out of the animal's system. These "stomach stones" tend to range in size from 1 to 6 centimeters. Larger sizes are known but very rare. Sometimes tiny dimples cover the surface of a stomach stone, which can fool observers into thinking they are the pores of an egg. Fossil egg expert Ken Carpenter has described stomach stones as the most egg-like natural objects, noting that they are "the trickiest [egg-like] objects to correctly identify". Calculi are so egg-like that on one occasion a detailed description of a stomach stone misidentified as a fossil egg was published in the scientific literature. Calculi can be distinguished from real egg fossils because when they are broken open, they show the layers of calcium phosphate and the foreign object at the core. Multiple layers of eggshell are known in pathological eggs, but these layers don't go all the way down to its core the way a stomach stone's do. Calculi are often suspiciously intact, unlike fossil eggs, which are usually damaged. Stomach stones also lack distinct shells with their attending structural components like continuous or prismatic layers, mammillae, and pores.
==== Pharmacokinetics of pyridine derivatives ==== Axitinib has short half-life, ranging from 2.5 to 6.1 hours, and therefore steady state should be reached in 2–3 days after the first dose. Peak plasma concentration is reached in 2.5 to 4.1 hours. In vitro protein binding is over 99%. Axitinib is primarily metabolized in the liver by CYP3A4/5. 30-60% of the drug is excreted in faeces, and about 23% in urine. Regorafenib is a pyridine derivative, but also a urea derivative and has therefore been covered in that section.
=== Underreporting in men === Men often do not report a personal issue of BED. Underreporting could be a result of measurement bias due to how eating disorders are defined. The current definition for eating disorders focuses on thinness. However, eating disorders in men tend to center on muscularity and would therefore warrant a need for a different measurement definition. Overvaluation rates of body weight or shape in adolescent males are significantly lower than their female counterparts (4.9% and 24.2%, respectively). Little is known if this discrepancy is an indicator of later onset of body image distortion in males or a consequence of female-centric diagnostic frameworks for eating disorders. The lack of representation of men in eating disorder research has been hindered by historical perceptions of eating disorders as a "female phenomenon". Researchers have been called on to address this gap by advancing methods of "identification, assessment, classification, and treatment" for eating disorders in a male-specific context, specifically in young men.
Sources: en.wikipedia.org
=== RNA editing and the genome === Octopuses, like other coleoid cephalopods but unlike more basal cephalopods or other molluscs, are capable of greater RNA editing, changing the nucleic acid sequence of the primary transcript of RNA molecules, than any other organisms. Much editing is done in the nervous system, particularly for excitability and neuronal morphology. Coleoids rely mostly on ADAR enzymes for RNA editing, which requires large, double-stranded RNA structures. The many editing sites are conserved in the coleoid genome and the mutation rates for the sites are hampered. Hence, greater transcriptome plasticity has come at the cost of slower genome evolution. The genome of octopuses has also gone through several chromosomal fusions and rearrangements, unlike that of their closest relative the vampire squid, whose chromosomal structure is more basal and squid-like. The octopus genome is unremarkably bilaterian except for large developments of two gene families: protocadherins, which regulate the development of neurons; and the C2H2 zinc-finger transcription factors. Many novel genes in both cephalopods generally and octopus specifically manifest in the animals' skin, suckers, and nervous system.
Quinolone antibiotics constitute a large group of broad-spectrum bacteriocidals that share a bicyclic core structure related to the substance 4-quinolone. They are used in human and veterinary medicine to treat bacterial infections, as well as in animal husbandry, specifically poultry production. Quinolone antibiotics are classified into four generations based on their spectrum of activity and chemical modifications. The first-generation quinolones, such as nalidixic acid, primarily target Gram-negative bacteria and are mainly used for urinary tract infections. Second-generation quinolones introduced fluorine atoms into their structure, creating fluoroquinolones, which significantly expanded their antibacterial activity to include some Gram-positive bacteria. Third-generation fluoroquinolones further improved Gram-positive coverage, while fourth-generation fluoroquinolones offer broad-spectrum activity, including anaerobic bacteria. Only quinolone antibiotics in generation two and higher are considered fluoroquinolones, as they contain a fluorine atom in their chemical structure and are effective against both Gram-negative and Gram-positive bacteria. One example is ciprofloxacin, one of the most widely used antibiotics worldwide.
=== Physical properties === Indigoidine is a blue amorphous powder that is insoluble in water and most other solvents, but dissolves in hydrochloric acid, producing a royal blue color, and in hot sulfuric acid, producing an orange-brown color.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.